首页> 外文OA文献 >OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis

【2h】

OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis

机译：OP24一种新型皮下注生素（CT-P13）：1年的结果，包括活性克罗恩病和溃疡性结肠炎患者静脉内英夫利昔单抗（CT-P13）的切换结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
S Ben-Horin; J Leszczyszyn; R Dudkowiak; A Lahat; B Gawdis-Wojnarska; A Pukitis; M Horynski; K Farkas; J Kierkus; M Kowalski; B D Ye; W Reinisch; S J Lee; S H Kim; M R Kim; Y A Kim; H N Kim; S Schreiber;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center [J] . Farkas Klaudia, Rutka Mariann, Ferenci Tamas, Expert opinion on biological therapy . 2017,第7a12期

机译：英夫利昔单抗生物纤维单体综合体CT-P13疗法在克罗恩病和溃疡性结肠炎的缓解方面是有效和安全的 - 从单一中心的经验
2. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis [J] . Keil Radan, Wasserbauer Martin, Zadorova Zdena, Scandinavian journal of gastroenterology. . 2016,第9期

机译：临床监测：英夫利昔单抗生物仿制性CT-P13治疗克罗恩病和溃疡性结肠炎
3. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center [J] . Farkas Klaudia, Rutka Mariann, Balint Anita, Expert opinion on biological therapy . 2015,第9期

机译：新型英夫利昔单抗生物仿制药CT-P13诱导疗法在克罗恩病和溃疡性结肠炎中的功效-单一中心的经验
4. Understanding Crohn's disease patients reaction to infliximab from facebook: A medical perspective [C] . M. Roccetti, P. Salomoni, C. Prandi, Proceedings of the 2016 IEEE/ACM International Conference on Advances in Social Networks Analysis and Mining . 2016

机译：从facebook了解克罗恩病患者对英夫利昔单抗的反应：医学观点
5. A Cost-utility Analysis of Biosimilar Infliximab Compared to Reference Infliximab in Adult Switch Patients with Crohn's Disease: A Canadian Analysis [D] . Hughes, Avery. 2018

机译：生物纤维生素infiximab的成本实用性分析与成人交换患者参考incriximab患者克罗恩病患者：加拿大分析
6. Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn’s disease or ulcerative colitis [O] . Cristian Gheorghe, Pavel Svoboda, Bogdan Mateescu 2019

机译：生物仿制药英夫利昔单抗（CT-P13）在克罗恩病或溃疡性结肠炎患者的现实生活中的有效性和安全性
7. DOP062 Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial [O] . K.K. Jørgensen, I.C. Olsen, G.L. Goll, 2017

机译：DOP062 BioSimilar Flowiximab（CT-P13）不逊于发起者Infliximab：来自Nor-Switch试验的Crohn病和溃疡性结肠炎的探索性IBD亚组分析

OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis

著录项

引文网络

相似文献

相关主题

期刊订阅